Published in Antimicrob Agents Chemother on February 01, 2003
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol (2007) 1.38
Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol (2004) 1.30
Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother (2006) 1.27
Tick-borne encephalitis virus delays interferon induction and hides its double-stranded RNA in intracellular membrane vesicles. J Virol (2010) 1.27
Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother (2011) 1.07
A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology (2009) 1.05
C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res (2008) 1.04
Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. Virology (2006) 0.97
The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother (2004) 0.92
Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res (2006) 0.85
Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection. Antiviral Res (2006) 0.80
Type I Interferon response in olfactory bulb, the site of tick-borne flavivirus accumulation, is primarily regulated by IPS-1. J Neuroinflammation (2016) 0.78
Dengue and dengue hemorrhagic fever. Clin Microbiol Rev (1998) 19.59
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet (1999) 3.80
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet (2001) 2.23
Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol (2000) 1.88
Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berl) (2001) 1.59
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology (2000) 1.44
Genotypic and phenotypic variation of selected Saint Louis encephalitis viral strains isolated in California. Am J Trop Med Hyg (1997) 1.24
Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly (I).poly (C). Am J Trop Med Hyg (1977) 1.22
Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol (2000) 1.17
Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother (2001) 1.16
New therapeutic strategies for hepatitis C. Hepatology (2002) 1.12
Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs (2001) 1.02
A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology (2001) 1.02
The molecular biology of tick-borne encephalitis virus. Review article. APMIS (1993) 1.01
EEG in Japanese encephalitis: a clinico-radiological correlation. Electroencephalogr Clin Neurophysiol (1998) 0.98
Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J Interferon Res (1990) 0.98
Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res (1999) 0.94
Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol (1998) 0.92
Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis (1987) 0.92
Prognosis of Japanese encephalitis: a multivariate analysis. J Neurol Sci (1998) 0.92
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res (2001) 0.91
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat (1998) 0.90
Enhanced resistance of mice to virulent Japanese B encephalitis virus following inactivated vaccine and poly I:C. J Infect Dis (1970) 0.85
The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health (1985) 0.84
Australian X disease, Murray Valley encephalitis and the French connection. Vet Microbiol (1995) 0.83
The influence of Poly I:C on the course of infection in mice inoculated with West Nile virus. Arch Gesamte Virusforsch (1971) 0.80
[The influence of the interferon-inducing compound Poly I:C on the experieental infection with tick-borne encephalitis (TBE) virus]. Zentralbl Bakteriol Orig (1969) 0.79
West Nile virus: a newly emergent epidemic disease. Emerg Infect Dis (2001) 0.78
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis (2013) 7.83
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature (2013) 6.39
Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis (2013) 5.25
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2002) 4.91
Bats host major mammalian paramyxoviruses. Nat Commun (2012) 4.15
LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem (2003) 3.97
Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio (2012) 3.96
Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur J Med Chem (2006) 3.79
Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis (2014) 3.74
Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis (2013) 3.61
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis (2014) 3.25
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology (2009) 3.16
Detection and prevalence patterns of group I coronaviruses in bats, northern Germany. Emerg Infect Dis (2008) 3.00
Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis (2009) 2.86
Circulation of group 2 coronaviruses in a bat species common to urban areas in Western Europe. Vector Borne Zoonotic Dis (2010) 2.65
Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion (2002) 2.53
Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg Infect Dis (2009) 2.52
Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Farmaco (2002) 2.47
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Circulation of 3 lineages of a novel Saffold cardiovirus in humans. Emerg Infect Dis (2008) 2.35
Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis (2008) 2.29
Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 2.28
Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev (2005) 2.24
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis (2010) 2.19
Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio (2013) 2.17
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother (2005) 2.14
RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans R Soc Trop Med Hyg (2007) 2.10
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol (2013) 2.10
Henipavirus RNA in African bats. PLoS One (2009) 2.10
High prevalence of common respiratory viruses and no evidence of Middle East respiratory syndrome coronavirus in Hajj pilgrims returning to Ghana, 2013. Trop Med Int Health (2015) 2.09
Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J Infect Dis (2013) 2.06
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem (2006) 2.04
Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco (2002) 2.04
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Amplification of emerging viruses in a bat colony. Emerg Infect Dis (2011) 1.98
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties. Bioorg Med Chem Lett (2003) 1.97
Chikungunya fever in travelers: clinical presentation and course. Clin Infect Dis (2007) 1.93
Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis (2003) 1.91
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg Infect Dis (2014) 1.89
Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray. J Clin Microbiol (2007) 1.89
Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87
Prevalence, types, and RNA concentrations of human parechoviruses, including a sixth parechovirus type, in stool samples from patients with acute enteritis. J Clin Microbiol (2007) 1.79
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
Spectrum of viruses and atypical bacteria in intercontinental air travelers with symptoms of acute respiratory infection. J Infect Dis (2007) 1.75
Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol (2004) 1.74
Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect (2002) 1.71
MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis (2014) 1.71
Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. J Virol (2012) 1.69
Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem (2006) 1.68
Crimean-Congo hemorrhagic fever in Kosovo. J Clin Microbiol (2002) 1.64
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem (2009) 1.64
Diagnosing schistosomiasis by detection of cell-free parasite DNA in human plasma. PLoS Negl Trop Dis (2009) 1.63
In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol (2003) 1.63
Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis (2006) 1.62
Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol (2003) 1.61
Hantavirus in bat, Sierra Leone. Emerg Infect Dis (2012) 1.60
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother (2004) 1.60
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur J Med Chem (2007) 1.60
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 1.59
Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. Molecules (2007) 1.55
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (2004) 1.55
Evidence for novel hepaciviruses in rodents. PLoS Pathog (2013) 1.54
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Coronavirus antibodies in African bat species. Emerg Infect Dis (2007) 1.54
Clinical features and treatment of adenovirus infections. Rev Med Virol (2008) 1.53
Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. Emerg Infect Dis (2007) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
A novel diagnostic target in the hepatitis C virus genome. PLoS Med (2009) 1.52
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem (2002) 1.51
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother (2011) 1.51
Selective inhibitors of picornavirus replication. Med Res Rev (2008) 1.50
A case for developing antiviral drugs against polio. Antiviral Res (2008) 1.50
NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion (2004) 1.49
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. J Clin Microbiol (2010) 1.45
In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol (2011) 1.45
Antiviral therapy: quo vadis? Future Med Chem (2010) 1.44
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol (2011) 1.44
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun (2004) 1.42